Frankfurt - Delayed Quote EUR

Chimerix, Inc. (CXF.F)

3.1350

-0.2000

(-6.00%)

At close: January 10 at 9:55:01 PM GMT+1

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit FacilityDURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today confirms that the Company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking accelerated approval for dordavipron

GlobeNewswire 13 days ago

CMRX
3 Promising Penny Stocks With Market Caps Under $2B In US

As U.S. markets experience a slight pullback with the S&P 500 and Nasdaq Composite shedding some recent gains, investors are closely watching for opportunities amid fluctuating indices. For those looking to invest in smaller or newer companies, penny stocks—despite the name's vintage feel—can still offer surprising value. These stocks, often overlooked, can present compelling opportunities when backed by strong financials and growth potential, making them attractive options for investors...

Simply Wall St. last month

CPIX

INTR

CMRX
Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were softer late Tuesday afternoon, with the NYSE Health Care Index and the Healt

PREMIUM
MT Newswires last month

CMRX
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy

Chimerix shares double as FDA filing for groundbreaking glioma treatment sparks investor excitement.

GuruFocus.com last month

CMRX
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?

On Monday, Chimerix (NASDAQ:CMRX) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone for recurrent H3 K27M-mutant diffuse glioma in the U.S. before year-end. A glioma is a tumor that originates in the glial cells of the brain or spinal cord and is the most common primary brain tumor. Chimerix stock is trading higher on a strong session volume of 4.31 million, compared to an ave

Benzinga last month

CMRX
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogu

GlobeNewswire last month

CMRX
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 385,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing r

GlobeNewswire last month

CMRX
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting

DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced upcoming presentations at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting, which will be held in Houston, TX from November 21 – 24, 2024. “We are excited to provide an updated assessment of objective response to dordaviprone previously reported in th

GlobeNewswire 2 months ago

CMRX
Chimerix Third Quarter 2024 Earnings: Misses Expectations

Chimerix ( NASDAQ:CMRX ) Third Quarter 2024 Results Key Financial Results Net loss: US$22.9m (loss narrowed by 4.6...

Simply Wall St. 2 months ago

CMRX
Q3 2024 Chimerix Inc Earnings Call

Q3 2024 Chimerix Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

CMRX
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ...

Chimerix Inc (CMRX) showcases progress in its drug pipeline and strong cash position, despite reporting a net loss and increased R&D expenses.

GuruFocus.com 2 months ago

CMRX
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of -8.33% and 97.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

CMRX
Chimerix: Q3 Earnings Snapshot

DURHAM, N.C. (AP) — Chimerix Inc. CMRX) on Thursday reported a loss of $22.9 million in its third quarter. The Durham, North Carolina-based company said it had a loss of 26 cents per share.

Associated Press Finance 2 months ago

CMRX
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment with TGA to Submit Dordaviprone for Provisional Approval in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and ext

GlobeNewswire 2 months ago

CMRX
LiveOne Leads The Pack Of 3 US Penny Stocks

As the U.S. stock market navigates a landscape shaped by tech earnings and labor market data, investors are keenly observing how these factors influence broader economic conditions. Penny stocks, despite being an older term, continue to capture attention for their potential to offer growth opportunities at lower price points. When these smaller or newer companies exhibit strong financial health and promising fundamentals, they can present compelling opportunities for investors seeking value...

Simply Wall St. 2 months ago

LYEL

LVO

CMRX
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview. To access the live conference call, please dia

GlobeNewswire 2 months ago

CMRX
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 130,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment in accordance with Nasdaq Listing rule

GlobeNewswire 2 months ago

CMRX
Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 3 months ago

CMRX
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference

DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will present a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET. An audio webcast of the presentation will be avail

GlobeNewswire 4 months ago

CMRX
Q2 2024 Chimerix Inc Earnings Call

Q2 2024 Chimerix Inc Earnings Call

Thomson Reuters StreetEvents 4 months ago

CMRX

Performance Overview

Return	CXF.F	S&P 500
YTD	-8.87%	-1.35%
1-Year	+240.76%	+22.51%
3-Year	-40.11%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Chimerix, Inc. (CXF.F)

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

3 Promising Penny Stocks With Market Caps Under $2B In US

Sector Update: Health Care Stocks Decline Late Afternoon

Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy

Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting

Chimerix Third Quarter 2024 Earnings: Misses Expectations

Q3 2024 Chimerix Inc Earnings Call

Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ...

Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates

Chimerix: Q3 Earnings Snapshot

Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

LiveOne Leads The Pack Of 3 US Penny Stocks

Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Q2 2024 Chimerix Inc Earnings Call

Performance Overview